



Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Center – WO66-G609  
Silver Spring, MD 20993-0002

Toshiba Medical Systems Corporation  
% Mr. Orlando Tadeo, Jr.  
Manager, Regulatory Affairs  
Toshiba America Medical Systems, Inc.  
2441 Michelle Drive  
TUSTIN CA 92780

November 26, 2014

Re: K141741  
Trade/Device Name: Aquilion PRIME, v6.00  
Regulation Number: 21 CFR 892.1750  
Regulation Name: Computed tomography x-ray system  
Regulatory Class: II  
Product Code: JAK  
Dated: October 23, 2014  
Received: October 24, 2014

Dear Mr. Tadeo:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, “Misbranding by reference to premarket notification” (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH’s Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

A handwritten signature in black ink that reads "Robert A. Ochs". The signature is written in a cursive style. Behind the signature, there is a faint, semi-transparent watermark of the FDA logo.

for

Janine M. Morris  
Director  
Division of Radiological Health  
Office of In Vitro Diagnostics  
and Radiological Health  
Center for Devices and Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known)

K141741

Device Name

Aquilion PRIME, TSX-303A/A, 303A/B and 303A/F, V6.00

Indications for Use (Describe)

This device is indicated to acquire and display cross-sectional volumes of the whole body, to include the head.

The Aquilion Prime has the capability to provide volume sets. These volume sets can be used to perform specialized studies, using indicated software/hardware, by a trained and qualified physician.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

**PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON A SEPARATE PAGE IF NEEDED.**

### FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

This section applies only to requirements of the Paperwork Reduction Act of 1995.

**\*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\***

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services  
Food and Drug Administration  
Office of Chief Information Officer  
Paperwork Reduction Act (PRA) Staff  
[PRASStaff@fda.hhs.gov](mailto:PRASStaff@fda.hhs.gov)

*“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.”*

**510(k) SUMMARY**

**1. SUBMITTER'S NAME:**

Toshiba Medical Systems Corporation  
1385 Shimoishigami  
Otawara-Shi, Tochigi-ken, Japan 324-8550

**2. OFFICIAL CORRESPONDENT:**

Akinori Hatanaka  
Senior Manager, Regulatory Affairs and Vigilance

**3. ESTABLISHMENT REGISTRATION:**

9614698

**4. CONTACT PERSON:**

Orlando Tadeo, Jr.  
Manager, Regulatory Affairs  
Toshiba America Medical Systems, Inc  
2441 Michelle Drive  
Tustin, CA 92780  
(714) 669-7459

**5. Date Prepared:**

June 26, 2014

**6. TRADE NAME(S):**

Aquilion PRIME, TSX-303A/A, 303A/B and 303A/F, v6.00

**7. COMMON NAME:**

System, X-ray, Computed Tomography

**8. DEVICE CLASSIFICATION:**

Class II (per 21 CFR 892.1750)

**9. PRODUCT CODE / DESCRIPTION:**

JAK – System, Computed Tomography

**10. PERFORMANCE STANDARD:**

This device conforms to applicable Performance Standards for Ionizing Radiation Emitting Products [21 CFR, Subchapter J, Part 1020]

**11. PREDICATE DEVICE:**

Product	Marketed by	510(k) Number	Clearance Date
Aquilion PRIME, TSX-303A/2 and 303A/6, v5.00	Toshiba America Medical Systems	K130645	June 6, 2013

**12. REASON FOR SUBMISSION:**

Modification of a cleared device

**13. DEVICE DESCRIPTION:**

The **Aquilion PRIME TSX-303A/A and /B, v6.00** are 80-row CT Systems and the **TSX-303A/F, v6.00** is a 40-row CT system that is intended to produce axial scans of the whole body to include the head. These systems are based upon the technology and materials of previously marketed Toshiba CT systems.

**14. INDICATIONS FOR USE:**

This device is indicated to acquire and display cross-sectional volumes of the whole body, to include the head.

The Aquilion Prime has the capability to provide volume sets. These volume sets can be used to perform specialized studies, using indicated software/hardware, by a trained and qualified physician.

**15. SUBSTANTIAL EQUIVALENCE:**

The subject device is substantially equivalent to the TSX-303A/2 and /6, Aquilion Prime CT System, K130645, marketed by Toshiba America Medical Systems. The **Aquilion PRIME TSX-303A/A, 303A/B and 303A/F, v6.00**, incorporates modifications to the cleared device which include implementation of a new detector that meets the specifications of the current detector and addition of previously cleared optional software features. The method of operation, base software and manufacturing process remain unchanged from the cleared device.

A complete comparison table is included in this submission. See below for a brief summary of changes from TSX-303A/2 and 303A/6, Aquilion Prime CT System:

Item	Aquilion PRIME TSX-303A/A, 303A/B and 303A/F, v6.00	Aquilion PRIME TSX-303A/2 and 303A/6, v5.00
510(k) Number	This submission	K130645
Detector	896 channels × 80 rows	896 channels × 80 rows
Number of detector elements	80 x 0.5 mm rows	80 x 0.5 mm rows
Maximum scan slice thickness	40mm/rotation	40mm/rotation
Console Operating System	Microsoft Windows 7	Microsoft Windows XP

Previously cleared software options being implemented to the modified device:

SEMAR (Single Energy Metal Artifact Reduction)	Previously cleared under K132222
SURESubtraction Ortho	Previously cleared under K130960
Dual Energy System Package	Previously cleared under K132813

## 16. SAFETY:

The device is designed and manufactured under the Quality System Regulations as outlined in 21 CFR § 820 and ISO 13485 Standards. This device is in conformance with the applicable parts of the IEC60601-1, IEC60601-1-1, IEC60601-1-2, IEC60601-1-3, IEC60601-1-4, IEC60601-1-6, IEC60601-1-9, IEC60601-2-28, IEC60601-2-32, IEC60601-2-44, IEC60825-1, IEC62304, IEC62366, NEMA PS 3.1-3.18, NEMA XR-25 and NEMA XR-26. Additionally, this device complies with all applicable requirements of the radiation safety performance standards, as outlined in 21 CFR §1010 and §1020.

## 17. TESTING

Risk analysis and verification/validation testing conducted through bench testing are included in this submission which demonstrates that the requirements for the modifications made to the system have been met. The modified system was evaluated to assess detector sensitivity and noise properties which demonstrated improvement in both studies. Additional image quality metrics, utilizing phantoms, were conducted to validate that the subject device is substantially equivalent to the predicate device with regard to spatial resolution, CT number and contrast-to-noise ratio and uniformity performance. Representative diagnostic images, reviewed by an American Board Certified Radiologist, including brain, chest, abdomen and peripheral exams were also obtained using the subject device which demonstrates that the device produces images of diagnostic quality and; therefore, performs as intended.

Software Documentation for a Moderate Level of Concern, per the FDA guidance document, “Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices Document” issued on May 11, 2005, is also included as part of this submission.

Additionally, testing of the modified system was conducted in accordance with the applicable standards published by the International Electrotechnical Commission (IEC) for Medical Devices and CT Systems.

## **18. CONCLUSION**

The modifications incorporated into the **Aquilion PRIME TSX-303A/A, 303A/B and 303A/F, v6.00** do not change the indications for use or the intended use of the device. Based upon bench testing, representative clinical images, successful completion of software validation and application of risk management and design controls, it is concluded that the subject device is safe and effective for its intended use.